Advanced Development of Antiviral Prophylactics and Therapeutics (ADAPT) - Research Area 10
Final rept. 1 Mar 2011-31 May 2014
PROSETTA BIOCONFORMATICS INC SAN FRANCISCO CA
Pagination or Media Count:
The purpose of the proposed work is to continue the promising anti-hemorrhagic fever virus HFV drug discovery and lead optimization efforts previously initiated by Prosetta through significant advancement of at least two chemical series through the first critical steps toward filing a Investigational New Drug IND application efficacy, safety and mechanism of action. This project will launch from the advanced platform of lead of optimization of five Prosetta-identified compounds and will progress through target identification and efficacy assessment in rodents. Two of these advanced compounds have very strong nanomolar-to-low micromolar activity against all four HFV families studied - Arenaviridae, Bunyaviridae, Filoviridae and Flaviviridae.
- Medicine and Medical Research